Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics for patients with metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal ...

Liver diseases, especially fatty liver, are rising fast, even among non-drinkers. Liver specialist Dr Saurabh Sethi shares 9 ...

Liver diseases, especially fatty liver, are rising fast, even among non-drinkers. Liver specialist Dr Saurabh Sethi shares 9 ...

MASLD rates have decreased, whereas liver fibrosis and cirrhosis rates have increased among US patients with type 2 diabetes since 2017.

Traditional cardiovascular risk assessment tools underperform among individuals with metabolic dysfunction-associated steatotic liver disease.

Dr. Saurabh Sethi highlights the liver's regenerative ability but warns against irreversible damage from chronic injury caused by factors like alcohol and poor diet. He emphasizes the benefits of ...

Adding bile acids as farnesoid X receptor agonists to the culture medium supported the growth and development of unique stem ...

Liver cirrhosis is a serious condition. It damages the liver over time. Common causes include alcohol, hepatitis, and fatty ...

Metabolic dysfunction-associated steatotic liver disease (MASLD) affects nearly one in three adults around the globe. It ...

Kennedy Jr. and the members of his newly appointed vaccine panel are casting doubt on the hepatitis B vaccine and the ...

It's well-documented that Americans began drinking more during the pandemic. In Wisconsin, alcohol-related deaths increased ...